Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting

Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14

FATE : 4.37 (+1.16%)
Fate Therapeutics Reports Third Quarter 2017 Financial Results

Clinical Data from First Subjects in VOYAGE Study of FATE-NK100 for Acute Myelogenous Leukemia to be Presented at SITC 2017

FATE : 4.37 (+1.16%)
Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting

Oral Presentation Unveiling Generation of CD8αB T Cells from Engineered Pluripotent Cell Line for Off-the-Shelf CAR T-Cell Cancer Immunotherapy

FATE : 4.37 (+1.16%)
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 4.37 (+1.16%)
Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune(TM) for Prevention of Acute Graft-versus-Host Disease

Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment

FATE : 4.37 (+1.16%)
Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development

Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company...

FATE : 4.37 (+1.16%)
5 Top-Ranked Biotech Stocks to Buy Right Now

If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

SGMO : 14.63 (+0.21%)
LGND : 140.31 (-0.99%)
GILD : 72.44 (+0.04%)
REGN : 391.59 (-0.79%)
KITE : 179.99 (+0.11%)
FATE : 4.37 (+1.16%)
ALXN : 110.87 (+0.49%)
Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko,...

WFC : 54.15 (-0.82%)
FATE : 4.37 (+1.16%)
BUYINS.NET: FATE SqueezeTrigger Price is $3.71. There is $6,823,423 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Fate Therapeutics (NASDAQ:FATE) in real time and just received an alert that FATE is crossing above its primary SqueezeTrigger Price, the price that a short squeeze...

FATE : 4.37 (+1.16%)
Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy

Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Patent...

FATE : 4.37 (+1.16%)
Fate Therapeutics Reports Second Quarter 2017 Financial Results

First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia

FATE : 4.37 (+1.16%)
Investor Network: Fate Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Fate Therapeutics, Inc. (NASDAQ: FATE) will be discussing their earnings results in their Q2 Earnings Call to be held on Monday, August 14, 2017 at 5:00 PM...

FATE : 4.37 (+1.16%)
Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 4.37 (+1.16%)
Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100

Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate

FATE : 4.37 (+1.16%)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 4.37 (+1.16%)
Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that...

FATE : 4.37 (+1.16%)
Surging Earnings Estimates Signal Good News for Fate Therapeutics (FATE)

Fate Therapeutics (FATE) could be an interesting play for investors as it sees solid activity on the earnings estimate revision.

FATE : 4.37 (+1.16%)
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro

Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro

CBAY : 8.66 (+1.64%)
BLDP : 4.67 (-0.43%)
FATE : 4.37 (+1.16%)
AINV : 6.07 (-0.49%)
OCLR : 6.58 (+3.46%)
Explosive Stocks Under $10

Explosive Stocks Under $10

CBAY : 8.66 (+1.64%)
BLDP : 4.67 (-0.43%)
FATE : 4.37 (+1.16%)
OCLR : 6.58 (+3.46%)
AINV : 6.07 (-0.49%)
Explosive Stocks Under $10

Explosive Stocks Under $10

CBAY : 8.66 (+1.64%)
BLDP : 4.67 (-0.43%)
FATE : 4.37 (+1.16%)
OCLR : 6.58 (+3.46%)
AINV : 6.07 (-0.49%)

Van Meerten Stock Picks

My 5 Favorite Small Caps
This morning I wanted to find the 5 Small Cap Stocks that had the best returns over the past year but still appeared to have some more room to climb.
SEDG -0.20 , GDOT +0.11 , CTRL -1.36 , ESIO -0.65 , QNST +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.06% ) this morning are down 0.06% on concern Special Counsel Mueller's criminal investigation between Trump campaign officials and Russia is deepening. Two people familiar with the matter... Read More

Chart of the Day

Chart of the Day

D R Horton (DHI) is the Barchart Chart of the Day.  The home builder has a Trend Spotter buy signal, a Weighted Alpha of 77.13+ and gained 68.46% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 4 – 6 1/2 cents higher, as Dec came back to only lose a half cent on the week. Pre-weekend profit taking gets some of the credit. The CFTC report on Friday showed the spec funds holding a new recor...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart